Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Connection study of IBP-9414 for prevention of necrotizing enterocolitis in very low birth weight premature infants
2018-000754-22Phase 3Unknown
- Sponsor
- Infant Bacterial Therapeutics
- Start
- Mar 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in necrotizing enterocolitis (NEC) comparing IBP-9414 with Placebo (2 arms). Primary endpoints: Prevention of necrotizing enterocolitis, Sustained feeding tolerance and 1 more. Status: unknown.
02
Drugs
IBP-9414
03
Conditions
necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on 2018-000754-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000754-22.